PHASE-II STUDY OF 13-CIS-RETINOIC ACID IN PEDIATRIC-PATIENTS WITH ACUTE NONLYMPHOCYTIC LEUKEMIA - A PEDIATRIC ONCOLOGY GROUP-STUDY

被引：11

作者：

BELL, BA

FINDLEY, HW

KRISCHER, J

WHITEHEAD, VM

HOLBROOK, T

HAGGARD, ME

KONRAD, PN

HENSLEY, M

RAGAB, AH

机构：

[1] Division of Pediatric Hematology/Oncology, Emory University, Atlanta, GA

来源：

JOURNAL OF IMMUNOTHERAPY | 1991年 / 10卷 / 02期

关键词：

ACUTE NONLYMPHOCYTIC LEUKEMIA; 13-CIS-RETINOIC ACID; SALVAGE THERAPY;

D O I：

10.1097/00002371-199104000-00001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Forty-one patients with refractory acute non-lymphocytic leukemia (ANLL) in relapse were treated with 13-cis-retinoic acid (cRA) as salvage therapy. The cRA was given as a single oral dose of 100 mg/m2/day for 4 weeks. One patient achieved a complete remission and two patients achieved a partial remission with reduction of the bone marrow blast count from 40 to 20% after the first course. We recommend further study of cRA in combination with other agents in the treatment of ANLL in children.

引用

页码：77 / 83

页数：7

共 26 条

[1]

BREITMAN TR, 1981, BLOOD, V57, P1000

[2] INDUCTION OF DIFFERENTIATION OF THE HUMAN PROMYELOCYTIC LEUKEMIA-CELL LINE (HL-60) BY RETINOIC ACID [J].